Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Elias J. Jabbour, MD, MD Anderson
Advertisement
Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Articles by Elias J. Jabbour, MD, MD Anderson
Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
Advertisement
Latest Updated Articles
ASH 2021: Novel Therapy in Acute Lymphocytic LeukemiaPublished: January 31st 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5